Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.69 |
| ▸ | IKBKB | O14920 | 9/20 | 0.63 |
| ▸ | CHUK | O15111 | 3/20 | 0.63 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.56 |
| ▸ | DKK1 | O94907 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14021520 | 0.91 | IKBKB (0.55) | MAPK8MAPK10IKBKBCHUKGSK3B | |
| SCHEMBL11924742 | 0.90 | IKBKB (0.63) | MAPK8MAPK10IKBKBCHUKGSK3B | |
| SCHEMBL8312592 | 0.89 | MAPK8 (0.78) | MAPK8MAPK10IKBKBCHUKCAMKK2 | |
| SCHEMBL4073555 | 0.85 | MAPK8 (0.67) | MAPK8MAPK10IKBKBCHUKCAMKK2 | |
| SCHEMBL4064743 | 0.84 | IKBKB (0.70) | MAPK8MAPK10IKBKBCHUKCAMKK2 | |
| SCHEMBL4073695 | 0.84 | MAPK8 (0.65) | MAPK8MAPK10IKBKBCHUKCAMKK2 | |
| SCHEMBL8246523 | 0.82 | MAPK8 (1.00) | MAPK8MAPK10IKBKBCHUKCAMKK2 | |
| SCHEMBL8866192 | 0.80 | KDM4E (0.61) | — | |
| SCHEMBL13911505 | 0.79 | IKBKB (0.64) | MAPK8MAPK10IKBKBCHUKCAMKK2 | |
| SCHEMBL4800404 | 0.79 | MAPK8 (0.83) | MAPK8MAPK10IKBKBCHUKCAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | MAPK8 25/4885MAPK10 12/4885IKBKB 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.